Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]

DRUG5 trials

Sponsors

University of Leipzig, 4D pharma plc, Henry Ford Health System, The Christie NHS Foundation Trust, West German Study Group

Conditions

Bladder CancerBreast CancerHNSCCHead and Neck NeoplasmsMelanomaMetastatic Renal Cell CarcinomaNon Small Cell Lung CancerOncology

Early Phase 1

HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

CompletedNCT04188951

Henry Ford Health SystemHead and Neck Neoplasms

Start: 2019-10-04End: 2024-05-08Updated: 2024-12-04

Phase 1

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

TerminatedNCT03637803

4D pharma plcBladder Cancer, Melanoma, Non Small Cell Lung Cancer +3

Start: 2019-01-10End: 2023-05-08Updated: 2023-06-01

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

The Christie NHS Foundation TrustMetastatic Renal Cell Carcinoma

Start: 2021-04-28End: 2024-04-28Target: 21Updated: 2022-08-23

Phase 2

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

CompletedNCT03480672

University of LeipzigHNSCC

Start: 2018-08-06End: 2025-01-30Updated: 2026-02-17

Phase 3

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Not yet recruitingNCT07178730

West German Study GroupBreast Cancer, Triple-negative Breast Cancer

Start: 2026-01-31End: 2033-03-31Target: 765Updated: 2025-09-17

Related Papers

The European Larynx Organ Preservation Study [MK-3475-C44]

Frontiers in Oncology2024-08-226 citations

838 Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation

Regular and Young Investigator Award Abstracts2022-11-011 citations

805 Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours

2020-11-014 citations

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Regular and Young Investigator Award Abstracts2020-11-013 citations

376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors

Regular and Young Investigator Award Abstracts2020-11-012 citations

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.

Journal of Clinical Oncology2019-05-205 citations